Prudential plc: My Outlook For 2026 Mirrors Global Insurance

Rising claims costs, technological disruption, and opaque AI-driven risk models challenge Prudential’s ability to deliver ...

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...

Medicus Pharma Ltd: Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development ...
Young and the Invested on MSN

13 best mutual funds for 13 different strategies

Mutual funds might not be the new hotness anymore. Exchange-traded funds (ETFs) clearly have stolen their thunder. But the ...
TechAnnouncer

Exploring the Techstars NYC Accelerator: A Look at New York’s Premier Startup Hub

New York City is buzzing with startups, and at the heart of it all is the Techstars NYC accelerator. It’s a big deal for anyone looking to get their tech idea off the ground. This article takes a look ...

ams OSRAM Post Q4 Above Mid-point of Guidance, Delivers EUR 144 m FCF in FY25 and Launches EUR 200 m 'Simplify' Transformation and Savings Program

Revenues EUR 874 m 18.4 adj. EBITDA margin, above the midpoint of guidance +8 growth yoy in like-for-like semiconductor core portfolio at constant FX FCF ...